CASE REPORT

Prolonged jaundice and hypothyroidism as the presenting symptoms in a neonate with a novel Prop1 gene mutation (Q83X)

Antonis Voutetakis, Maria Maniati-Christidi, Christina Kanaka-Gantenbein, Maria Dracopoulou, Maria Argyropoulou, Sarantis Livadas, Catherine Dacou-Voutetakis and Amalia Sertedaki

Endocrine Unit, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Goudi, Athens 115 27, Greece

(Correspondence should be addressed to A Sertedaki; Email: aserted@med.uoa.gr)

Abstract

Objective: To identify the genetic defect in a neonate presented with prolonged jaundice and central hypothyroidism.

Design: Central hypothyroidism was detected in a neonate initially examined for prolonged jaundice, and levothyroxine therapy was initiated. Direct sequencing of the Prop1 gene was carried out and pituitary function and morphology were evaluated using hormonal testing and magnetic resonance imaging (MRI) respectively.

Methods: Dynamic hormonal testing was carried out using established methodologies. Hormones were determined by RIA or chemiluminescence immunoassays. Genomic analysis of the Prop1 gene was performed by direct sequencing. MRI protocol: sagittal spin echo T2-weighted scans 2500/90 (TR/TE), plain and contrast-enhanced sagittal and coronal spin echo T1-weighted scans 500/20 (TR/TE).

Results: Low thyroid hormones (coupled with lack of TSH rise), low GH, normal cortisol and normal prolactin values were detected. Direct sequencing revealed the presence of two mutations in the Prop1 gene: GA296del and Q83X. The Q83X was further confirmed by PvuII restriction digestion and represented a novel Prop1 gene mutation, which was not detected in 100 controls tested. Pituitary enlargement was detected, with respect to normal-for-age controls.

Conclusions: (i) The Q83X mutation extends the spectrum of Prop1 gene mutations; (ii) central hypothyroidism in a neonate might constitute the initial sign of Prop1 gene defect; (iii) the patient is the youngest individual with Prop1 gene defect and pituitary enlargement presented to date; and (iv) early detection of Prop1 gene mutations facilitates genetic counseling and ensures prompt management of the anticipated hormonal insufficiencies.

European Journal of Endocrinology 150 257–264

Introduction

The ontogenesis of the anterior pituitary gland constitutes a complex and multifarious process. The most important transcription factors guiding the evolution of the adenohypophysis are: Hesx1 (1), Pitx1 (2), Pitx2 (3), Lhx3 (4), Lhx4 (5), Prop1 (6) and Pit1 (POU1F1) (7). Mutations in these tissue-specific transcription factors cause insufficient synthesis of more than one pituitary hormone.

The Prop1 gene is located on chromosome 5q35, consists of three exons and two introns and encodes a protein of 226 amino acids (6). The various molecular defects of the Prop1 gene, thus far reported, are deletions or substitutions in the DNA-binding domain (exons 2 and 3), in the transcriptional activation domain (exon 3) and in the intron–exon boundaries (8–15). The most frequently observed Prop1 gene mutation is a GA deletion at nucleotide 296 (GA296del) (16–17). Pathogenic Prop1 gene alterations lead to combined pituitary hormone deficiency (CPHD): growth hormone (GH), prolactin (PRL), thyrotropin (TSH) and gonadotropins of variable severity and timing of onset. Adrenocorticotropin insufficiency occasionally develops as a rather late manifestation of unknown pathogenesis (11, 12, 18, 19). Insufficient adrenarche in the presence of a normal pituitary–adrenal axis has also been reported (20). Pituitary morphology in patients with Prop1 gene defects varies: a normal pituitary gland has been demonstrated in some cases, while in others pituitary hypoplasia, hyperplasia or adenoma have been detected (12, 21–23).

In the present communication, we describe an infant presented with prolonged neonatal jaundice and low thyroid hormones, without TSH rise, caused by compound heterozygosity of the Prop1 gene. One of the
mutations detected (Q83X) constitutes a novel Prop1 gene defect.

**Patient and methods**

**Patient presentation, evaluation and treatment**

The infant was born at term following an uneventful pregnancy and normal delivery to a gravida II para II mother. He cried immediately and no perinatal or neonatal problems were noted. The birth weight was 3300 g and the birth length was 52 cm. The neonatal screening for congenital hypothyroidism (using TSH determination) was normal, as expected.

The parents were healthy and reportedly unrelated. The father’s height was 179 cm, the mother’s 157 cm and the infant’s target height was 174.5 cm (standard deviation score: $-0.4$). The patient’s older sister, aged 3 years, was healthy and of normal linear growth. She was operated upon for thyroglossal cyst at the age of 2 years.

The patient was initially examined at the age of 40 days because of prolonged jaundice and elevated liver enzymes. At the time, he was exclusively breast-fed. The total bilirubin (normal value (NV) $< 1$ mg/dl) was 8.2 mg/dl (direct 0.7 mg/dl). The liver enzymes were serum glutamic-oxaloacetic transaminase (SGOT): 106 IU/l (NV: 10–60 IU/l), serum glutamic-pyruvic transaminase (SGPT): 42 IU/l (NV: 5–45 IU/l), $\gamma$-glutamyltransferase ($\gamma$GT): 100 IU/l (NV: 2–50 IU/l) and the alkaline phosphatase was 310 IU/l (NV: 60–240 IU/l). Laboratory tests performed for hemolytic disease, hepatitis and congenital infections proved negative. As part of the diagnostic work up for the prolonged jaundice, the thyroid hormones were determined and the following results obtained: total thyroxine (T4) (TT4): 68.2 nmol/l (NV: 94–243 nmol/l), free T4 (FT4): 8.9 pmol/l (NV: 14.2–25.7 pmol/l), total triiodothyronine (T3) (TT3): 2.34 nmol/l (NV: 1.54–3.77 nmol/l), TSH: 2.9 mIU/l (NV: 0.5–6.46 mIU/l).

The infant was transferred to our endocrine unit at the age of 11 weeks. The physical examination showed the following: the body length was 58 cm, the weight 6 kg and the head circumference 40.5 cm. The anterior fontanel measured $2.5 \times 2.5$ cm. No clinical features of hypothyroidism were present except for mildly icteric conjunctivae. The testes (volume: 1.5 ml) were in situ and the penile length was normal. The rest of the physical examination was unremarkable. The thyroid hormones were low with no TSH increment (Table 1). The total bilirubin value was 2.4 mg/dl (direct 0.7 mg/dl) and the liver enzymes were: SGOT: 170 IU/l, SGPT: 125 IU/l and $\gamma$GT: 84 IU/l. Levothyroxine therapy was initiated at the age of 12 weeks (25 $\mu$g/day, which was raised to 50 $\mu$g/day at the age of 10 months). Thereafter, the thyroid hormone values have always been normal.

At the age of 16 weeks the liver enzymes were normal (SGOT: 45 IU/l, SGPT: 32 IU/l and $\gamma$GT: 39 IU/l).

The linear growth pattern before and after levothyroxine initiation is depicted in Fig. 1. The infant’s psychomotor development has been normal: he spoke his first words at the age of 10 months, walked at the age of 12 months, and formed three-word sentences at the age of 2 years. Due to the progressive failure of the linear growth curve we are in the process of starting human GH substitution therapy.

**Hormonal studies**

At 40 days, serum TT4, FT4, TT3 and TSH were determined using the electrochemiluminescence immunoassay method (Roche). At 11 weeks, FT4 and TSH were determined using the Nichols Advantage Chemiluminescence Immunoassay (Nichols Institute Diagnostics, San Juan Capistano, CA, USA). PRL, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were determined using the Automated Chemiluminescence System ACS: 180 (Bayer, Tarrytown, NY, Europe).

Cortisol, GH and insulin-like growth factor-I (IGF-I) were determined using the Nichols Advantage Chemiluminescence Immunoassay. Dehydroepiandrosterone sulfate (DHEAS) and testosterone were determined by RIA (Diagnostic Systems Laboratories, Webster, TX, USA).

The glucagon test was carried out after the i.m. administration of glucagon (100 $\mu$g/kg). Blood samples for GH and cortisol determinations were obtained prior to and 60, 90, 120, 150 and 180 min post-glucagon administration.

The gonadotropin-releasing hormone (GnRH) test was carried out after the i.v. administration of synthetic GnRH (100 $\mu$g). Blood samples for LH and FSH determinations were obtained prior to and 30 and 60 min post-GnRH administration.

The TRH test was carried out after the i.v. administration of synthetic TRH (200 $\mu$g). Blood samples for TSH and PRL determinations were obtained prior to and 30 and 60 min post-TRH.

**Pituitary magnetic resonance imaging (MRI)**

The MRI protocol consisted of sagittal spin echo T2-weighted scans 2500/90 (TR/TE), and plain
and contrast-enhanced sagittal and coronal spin echo T1-weighted scans 500/20 (TR/TE), with slice thickness 3 mm and 0.3 mm gap. The maximum height of the pituitary gland was measured perpendicular to the sella turcica. The pituitary gland was considered hypoplastic if the maximum height was less than –2 s.d. and hyperplastic if the maximum height was greater than 2 s.d., compared with normal controls (24, 25).

**Genomic analysis of the Prop1 gene**

The study was approved by the institutional review board and informed consent was obtained from each participant or their parents. One hundred control subjects were also included in the study. DNA was extracted from peripheral blood using the QIAmp DNA Blood mini kit (Qiagen, Hilden, Germany). Each one of the three exons of the Prop1 gene was PCR amplified. PCR was performed in a 50 μl reaction mixture containing 100 ng DNA, 25 μl Promega Mastermix (Promega Corporation, Madison, WI, USA) and 25 pmol of each primer. The following pairs of primers were used: exon 1 sense primer 5'-gagatgaggcctgtcttggtga-3'; and exon 3 sense primer 5'-ctcttgcatggaggtgtca-3', antisense primer 5'-cagacttctccactaactc-3'.

PCR amplification reaction consisted of one cycle at 94 °C for 3 min followed by 35 cycles of 30 s at 94 °C, 30 s at 56 °C, 1 min at 72 °C and one cycle of 5 min at 72 °C. The PCR products were cleaned with the Qiaquick PCR purification kit (Qiagen). The double-stranded PCR products of each exon were directly sequenced employing the Thermo Sequenase core sequencing kit on a VISTRA DNA Sequencer 725 (Amersham Pharmacia Biotech) using the following Texas Red-labeled primers: exon 1: 1S 5'-CCAAGGGGTGCTCAGTC-3' (sense), exon 2: 2S1 5'-TGGTCCAGCACCGAGGAG-3' (sense) and 2S2: 5'-TGCCCAACATTATGATAGC-3' (anti sense) and exon 3: 3S1: 5'-GTGGGCTCTGATGTGGTTC-3' (sense) and 3S2: 5'-CACCACCACCAGTGACCTG-3' (sense).

**Detection of the Q83X mutation by PvuII restriction digestion of exon 2**

PCR products were digested with 10 U PvuII (New England Biolabs, Hertfordshire, UK) at 37 °C overnight. The resulting fragments (230 and 210 bp) were analyzed in 4% (w/v) 3:1 NuSieve:Seakem (BMA BioProducts, Rockland, MD, USA) agarose gel and visualized by ethidium bromide staining.
Results

Hormonal studies

Hormonal studies showed low thyroid hormone values coupled with 'normal' TSH values at week 11. Ten days after levothyroxine initiation the thyroid hormone values were normal (Table 1).

The GH values were low and the cortisol values were normal after the glucagon test (18 months, Table 2). IGF-I values were very low (Table 3). The basal PRL values were normal at the age of 13 and 18 months and lower at 24 months with a small rise post-TRH (Tables 2 and 3). The basal gonadotropin values were within the normal range for the corresponding age, but the response to GnRH at 24 months was not adequate (Tables 2 and 3). Low normal testosterone value and normal DHEAS value were detected at the age of 3 months (Table 3).

MRI

The MRI of the pituitary gland, carried out at the age of 2.5 years, showed pituitary enlargement (Fig. 2A and B). The pituitary gland height was 8 mm (normal 4.0 ± 0.7 mm) (24) with no abnormalities of the neurohypophysis, the optic chiasm or the pituitary stalk.

Molecular studies

Direct sequencing of exon 2 of the Prop1 gene with two different primers (one in the sense and one in the antisense direction) revealed that the patient was a compound heterozygote for the mutation GA296del, inherited from his father, and the mutation C247T, inherited from his mother (Fig. 3). The C247T transition converts codon 83 (CAG) encoding glutamine into a termination codon (TAG) and constitutes a novel nonsense mutation (Q83X). This mutation should result in the production of a truncated peptide with only 82 of the 226 amino acids of the wild-type protein. The C247T mutation destroys a PvuII restriction site (CAG/CTG) and allows for the confirmation of the DNA sequencing results by restriction digestion. Hence, the absence of the PvuII restriction site confirmed the presence of the mutation (Fig. 4). Importantly, the mutation Q83X has not been detected in 100 DNA samples tested in our laboratory.

Discussion

We describe a full-term neonate presented with prolonged jaundice and elevated liver enzymes. The low values of thyroid hormones, coupled with lack of TSH rise, led to the tentative diagnosis of congenital central hypothyroidism: TRH receptor defects (26), alterations in the TSHβ-subunit (27, 28), or pituitary-specific transcription factors, such as Prop1 and Pit1 (29). Direct sequencing of the Prop1 gene revealed the specific pathogenic mutations. Later on, GH deficiency was suspected due to the absence of growth acceleration after levothyroxine therapy initiation, the declining growth curve and the low height with respect to the infant's

Table 2 Hormonal findings at different ages: dynamic tests.

<table>
<thead>
<tr>
<th>Time of sampling (min)</th>
<th>GH (μg/l)</th>
<th>Cortisol (nmol/l)</th>
<th>LH (IU/l)</th>
<th>FSH (IU/l)</th>
<th>TSH (mU/l)</th>
<th>PRL (μg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2.1</td>
<td>635</td>
<td>0.1</td>
<td>0.9</td>
<td>0.2</td>
<td>7.6</td>
</tr>
<tr>
<td>30</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>60</td>
<td>1.4</td>
<td>524</td>
<td>0.2</td>
<td>1.1</td>
<td>0.8</td>
<td>13.9</td>
</tr>
<tr>
<td>90</td>
<td>1.6</td>
<td>386</td>
<td>0.3</td>
<td>1.3</td>
<td>1.0</td>
<td>12.8</td>
</tr>
<tr>
<td>120</td>
<td>2.6</td>
<td>414</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>150</td>
<td>3.2</td>
<td>855</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>180</td>
<td>2.8</td>
<td>1021</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Peak normal values</td>
<td>&gt; 10</td>
<td>&gt; 690</td>
<td>1.4–6.0</td>
<td>2.3–6.9</td>
<td>&gt; 10</td>
<td>&gt; 20</td>
</tr>
</tbody>
</table>

LHRH, luteinizing hormone-releasing hormone. —, values not required for the times indicated.

Table 3 Hormonal findings at different ages: other hormonal findings.

<table>
<thead>
<tr>
<th>Age (months)</th>
<th>Testosterone (nmol/l)</th>
<th>DHEAS (nmol/l)</th>
<th>LH Basal (IU/l)</th>
<th>FSH Basal (IU/l)</th>
<th>PRL Basal (IU/l)</th>
<th>IGF-I (μg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1.59</td>
<td>1200</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>13</td>
<td>—</td>
<td>1200</td>
<td>&lt; 0.01</td>
<td>0.9</td>
<td>0.9</td>
<td>—</td>
</tr>
<tr>
<td>18</td>
<td>—</td>
<td>—</td>
<td>0.7</td>
<td>15.3</td>
<td>16.3</td>
<td>—</td>
</tr>
<tr>
<td>24</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.0</td>
<td>—</td>
</tr>
</tbody>
</table>

Normal values

<table>
<thead>
<tr>
<th>Age (months)</th>
<th>Testosterone (nmol/l)</th>
<th>DHEAS (nmol/l)</th>
<th>LH Basal (IU/l)</th>
<th>FSH Basal (IU/l)</th>
<th>PRL Basal (IU/l)</th>
<th>IGF-I (μg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1.1–5.0 (3–5 months)</td>
<td>117–2020 (&lt;1 year)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>—</td>
<td>&lt; 3.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>—</td>
<td>0.2–1.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>—</td>
<td>9.8–73.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

17–248
genetic potentials. GH deficiency, and therefore CPHD, was confirmed using appropriate studies (Tables 1–3). The molecular studies revealed compound heterozygosity for the mutations GA296del and Q83X; the latter reported for the first time. The novel mutation Q83X is a C to T transition at nucleotide 247 located in exon 2, resulting in a premature stop codon (CAG to TAG). The Q83X mutation is located in the highly conserved α-1 helix of the homeodomain that extends from amino acid 69 to amino acid 128. A comparison of this conserved amino acid sequence employing a Blast search (30) was carried out (SIB BLAST Network Service) and revealed that glutamine at codon 83 is conserved in several species: bovine, mouse, pig, dog and rat. Moreover, the protein resulting from this mutation is a truncated protein with only 82 out of the 226 amino acids forming the normal peptide. The functional consequences of this novel mutation are obvious since the truncated protein lacks both functional domains of the wild-type protein: the DNA-binding domain and the transactivation domain. It must be mentioned that previously reported mutations downstream of codon 83 result in truncated proteins, with complete loss of function (8). Therefore, the Q83X mutation should preclude binding of the transcription factor to its cognate DNA sites and result in complete loss of function. Alternatively, the nonsense transcript might not be translated to a truncated protein, but rather become degraded by the cell via the nonsense-mediated mRNA decay pathway (31). Importantly, the C to T transition at nucleotide 247 was not found in 100 normal individuals tested, excluding the possibility of a polymorphism.

Figure 2 Pituitary MRI of the patient with Prop1 gene defect (GA296del/Q83X). (A) Midsagittal plain T-weighted MRI scan shows pituitary enlargement with anterior displacement of the pituitary stalk (white arrow). The posterior lobe is in the normal position and exhibits a normal bright signal. (B) Coronal plain T1-weighted MRI scan shows pituitary gland enlargement without lateral deviation of the stalk.

Figure 3 Part of the automated fluorescence-based sequencing chromatogram of the second exon of Prop1 gene amplified from genomic DNA of (A) a normal individual and (B) the patient, heterozygous for the mutation Q83X. Normal (CAG) and mutant (YAG), nucleotide 247 is underlined. Y denotes C or T.
the presence of biologically inactive TSH molecules (34). In our patient, the moderate elevation of hepatic transaminases in the absence of an obvious pathogenetic mechanism, as well as their normalization shortly after euthyroidism was accomplished, must be attributed to hypothyroidism (35, 36). From the reports available, it has become evident that in patients with Prop1 gene defect, the severity and timing of hormonal insufficiency varies with no particular correlation between phenotype and genotype (33). In this regard, it is of interest to underscore certain features of the present case. The low normal testosterone levels in our infant at the age of 3 months indicate that, at least at this developmental stage, the testicular function was satisfactory. The normal penile size is confirmatory and favors the prediction of Parks et al. (29) that the size of the penis should be normal in infants with Prop1 gene defects. The normal-for-age value of DHEAS compared with insufficient function of the reticular zone (insufficient adrenarche) in pubertal and post-pubertal subjects with a Prop1 gene defect (20) constitutes an interesting observation. It can be attributed to diverse modulation of DHEAS production by the fetal and adult adrenals or possibly to later development of this insufficiency, as has also been reported for other hormones in Prop1-deficient patients. Furthermore, the basal PRL values in our patient were normal while in older patients they are usually reported as quite low (29). With regard to the gonadotropins, subnormal values in this age group are difficult to diagnose, since expected values are generally low (37).

The pituitary enlargement found in our patient has also been described in other cases with Prop1 gene defects (13, 21, 23, 38). However, we must underscore the very young age (2.5 years) at which the enlargement was detected in our patient, a finding indicative of an early initiation of the process responsible for the pituitary enlargement. Hence, it should be kept in mind that pituitary enlargement can occur quite early in patients with Prop1 gene defect and should be considered in the differential diagnosis of a pituitary mass or enlargement. The mechanism involved still remains enigmatic and quite speculative.

In conclusion: (i) the Q83X mutation extends the spectrum of Prop1 gene mutations; (ii) central hypothyroidism in a neonate might constitute the initial sign of Prop1 gene defect; (iii) the patient is the youngest individual with Prop1 gene defect and pituitary enlargement presented to date; and (iv) early detection of Prop1 gene mutations facilitates genetic counseling and ensures prompt management of the anticipated hormonal insufficiencies.

References

1 Thomas PQ, Dattani MT, Brickman J, McNay D, Warne G, Zacharin M et al. Heterozygous HESX1 mutations associated...
Novel Prop1 gene mutation

with isolated congenital pituitary hypoplasia and septo-optic dysplasia. 

Human Molecular Genetics 2001 10 39–45.


4 Netchine I, Sobrier ML, Krude H, Schnabl D, Maghnie M, Marcos E et al. Mutations in the LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. 


Mutations in familial combined pituitary hormone deficiency. 


7 Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanston LW & Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene Pit1. 


8 Wu W, Cogan JD, Pfiffle RW, Dusen JS, Frisch H, O’Connell SM et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. 

Nature Genetics 1998 18 147–149.


10 Teinturier C, Vallette S, Adamsbaum C, Bendaoud M, Brue T & Bougnères PE. Pseudotumor of the pituitary due to a PROP1 deletion. 


12 Tsunoda A, Okuda O & Sato K. MR height of the pituitary gland as a function of age and sex: especially physiological hypertrophy in adolescence and in climacterium. 


13 Krude H, Bieremann H, Schnabl D, Ambrugger P & Grütters A. Molecular pathogenesis of neonatal hypothryroidism. 

Hormone Research 2000 53 (Suppl 1) 12–18.

14 Sertedaki A, Papadimitriou A, Voutetakis A, Dracopoulou M, Maniati-Christidis M & Dakos-Voutetakis C. Low TSH congenital hypothyroidism: Identification of a novel mutation of the TSH beta-subunit gene in one sporadic case (C85R) and of mutation Q49stop in two siblings with congenital hyperthyroidism. 

Pediatric Research 2002 52 95–96.


18 Frischmeyer PA & Dietz HC. Nonsense-mediated mRNA decay in health and disease. 

Human Molecular Genetics 1999 8 1893–1900.

19 Cogan JD, Wu W, Phillips JA 3rd, Arnhold IJ, Agapito A, Fofanova OV et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. 


37 Elmlinger MW, Kühnel W & Ranke MB. Reference range for serum concentrations of leutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clinical Chemistry and Laboratory Medicine 2002 40 1151–1160.


Received 16 October 2003
Accepted 24 November 2003